Senior Correspondent, London
Ben's Feed
Jul 2, 2014
Jul 2, 2014

UK’s Cameron calls for global action on superbug threat

LONDON, July 2 (Reuters) – Prime Minister David Cameron
called on Wednesday for global action to tackle the threat of
drug-resistant superbugs and said Britain planned to take a
leading role in finding ways to spur the development of new
antibiotics.

A world without effective antibiotics would push medicine
back into the “dark ages”, he said, with routine surgery,
treatments for cancer and organ transplants potentially becoming
impossible.

Jul 1, 2014
Jul 1, 2014
Jun 30, 2014
Jun 27, 2014

Lilly wins EU backing for copy of Sanofi’s top insulin Lantus

LONDON (Reuters) – European regulators have for the first time recommended approval of a copycat insulin for diabetics, posing a threat to French drugmaker Sanofi whose top-selling Lantus is now set to face a cheaper rival in 2015.

The new drug, known as Abasria, is made by U.S. rival Eli Lilly, which has developed it as a so-called biosimilar version of Sanofi’s $8 billion-a-year Lantus, or insulin glargine.

Jun 27, 2014
Jun 27, 2014
Jun 26, 2014
Jun 26, 2014

Cancer drug setback tarnishes AstraZeneca’s R&D claims

LONDON, June 26 (Reuters) – A vote by U.S. experts against
accelerated approval of a new ovarian cancer drug from
AstraZeneca has dented its claims of research prowess,
which were used to see off a $118 billion bid from Pfizer
.

In itself, the setback will have little impact on earnings
prospects – but it coincides with heightened scrutiny of the
British drugmaker’s research and development (R&D) machine and
continued talk that Pfizer may return if it stumbles.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben